No Data
Shandong Buchang Pharmaceutical Co., Ltd. Report for the first quarter of 2025
Summary of the 2024 Annual Report of Shandong Buchang Pharmaceutical Co., Ltd.
Shandong Buchang Pharmaceutical Co., Ltd. 2024 Annual Report
Shandong Buchang Pharmaceuticals Co., Ltd. (SHSE:603858) Insiders Have Significant Skin in the Game With 58% Ownership
Shandong Buchang Pharmaceuticals (603858.SH): has repurchased a cumulative 0.29% of its shares.
On April 1, Gelonghui reported that Shandong Buchang Pharmaceuticals (603858.SH) announced that as of March 31, 2025, the company had repurchased a total of 3,210,530 shares through centralized bidding, accounting for 0.29% of the company's total share capital. The highest purchase price was 15.06 yuan per share, the lowest price was 14.55 yuan per share, and the total amount paid so far is 47,747,958.65 yuan (excluding transaction costs).
Shandong Buchang Pharmaceuticals (603858.SH): The marketing authorization holder of An Gong Niu Huang Wan has been changed from Liaoning Han Cao Tang to Shandong Buchang Pharmaceuticals.
On March 18, Gelonghui reported that Shandong Buchang Pharmaceuticals (603858.SH) announced that it recently received the "Approval Notice for Supplementary Application of Pharmaceuticals" issued by the National Medical Products Administration, agreeing to change the marketing authorization holder of An Gong Niu Huang Wan from Liaoning Hancatang to Shandong Buchang Pharmaceuticals. The official change of the marketing authorization holder of An Gong Niu Huang Wan to Shandong Buchang Pharmaceuticals is beneficial for expanding the company's Business, enriching the company's product line, and strengthening market competitiveness. It will not have a significant impact on the company's current Operation.
Shandong Buchang Pharmaceuticals (SHSE:603858) Shareholders Have Endured a 15% Loss From Investing in the Stock Three Years Ago
